Business Context and Reporting Period
Company: iRhythm Technologies, Inc. (IRTC)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: iRhythm is a digital healthcare company providing ambulatory cardiac monitoring services (Zio Services) via wearable biosensors and cloud-based analytics. The company operates as a single reporting segment focused on detecting, predicting, and preventing cardiac arrhythmias, primarily atrial fibrillation (Afib). As of December 31, 2024, the company employed approximately 2,000 full-time employees globally.
Key Financial Metrics
| Metric (in thousands, except per share) | 2024 | 2023 | Change |
|---|---|---|---|
| Revenue, Net | $591,839 | $492,681 | +20% |
| Gross Profit | $407,531 | $331,806 | +23% |
| Gross Margin | 69% | 67% | +200 bps |
| Net Loss | $(113,289) | $(123,406) | -8% (Improvement) |
| Net Loss Per Share (Basic & Diluted) | $(3.63) | $(4.04) | -10% |
| Adjusted EBITDA | $(7,748) | $(4,863) | Worsened |
| Cash and Cash Equivalents | $419,597 | $36,173 | Significant Increase |
| Marketable Securities | $115,956 | $97,591 | +19% |
| Total Debt (Convertible Notes) | $646,443 | $0 | New Issuance |
Note: 2024 Net Loss includes $32.4 million in acquired in-process research and development (IPR&D) expenses related to the BioIntelliSense license agreement.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 20% to $591.8 million, driven primarily by increased volume of Zio Services. Average selling price remained stable.
- Debt Financing: In March 2024, the company issued $661.3 million in 1.50% Senior Convertible Notes due 2029. Proceeds were used to repay prior term loans (SVB and Braidwell), purchase capped call transactions ($72.4 million), and repurchase $25.0 million of common stock.
- Strategic Acquisition: Entered a Technology License Agreement with BioIntelliSense, Inc. (BioIS) in August 2024. This resulted in a $15.0 million upfront cash payment and a $32.4 million non-cash IPR&D expense charge in 2024.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased 9% to $418.6 million, largely due to third-party patient claims processing fees and legal fees, partially offset by reduced stock-based compensation. Research and Development (R&D) expenses increased 19% to $71.5 million.
- Impairment Charges: Impairment and restructuring charges decreased significantly by 94% to $0.6 million in 2024, compared to $11.1 million in 2023 (which included a $9.9 million impairment of the San Francisco headquarters right-of-use asset).
- Liquidity: Cash and cash equivalents surged from $36.2 million in 2023 to $419.6 million in 2024, primarily due to the convertible note issuance.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook
- International Expansion: Commercial launch of Zio Monitor System and Services occurred in Austria, the Netherlands, Spain, and Switzerland in Q3 2024. Regulatory approval was granted in Japan in September 2024.
- Product Strategy: Focus on expanding into adjacent markets including obstructive sleep apnea, heart failure, and hypertension. The company is leveraging its data repository to develop AI-driven risk stratification for undiagnosed arrhythmias.
- Reimbursement: Approximately 24% of revenue is derived from Medicare. CMS updated reimbursement rates for 2025; rates for CPT codes 93247 and 93243 saw slight increases, while 93229 (MCT) decreased.
Key Risks and Contingencies
- Regulatory Enforcement: The company received FDA Form 483 observations in July 2024 regarding complaint handling, medical device reporting, and quality system requirements. The company is working with the FDA to resolve these issues. A prior FDA warning letter from May 2023 regarding the Zio AT System has been addressed with subsequent 510(k) clearances in October 2024.
- Legal Proceedings:
- Securities Litigation: A putative securities class action lawsuit was filed in February 2024 alleging violations of Sections 10(b) and 20(a) of the Exchange Act. A motion to dismiss was filed in December 2024.
- Patent Litigation: Two patent lawsuits were filed by Baxter International subsidiaries (Welch Allyn and Bardy Diagnostics) alleging infringement of Zio device patents. The company intends to defend vigorously.
- Government Investigations: The company is cooperating with a DOJ subpoena regarding product and service documentation.
- Cybersecurity: A cybersecurity incident at Change Healthcare (a third-party billing vendor) in Q1 2024 caused temporary billing delays, though the backlog was substantially cleared by the end of the quarter.
- Profitability: The company has a history of operating losses and an accumulated deficit of $758.9 million as of December 31, 2024. It expects to continue incurring operating losses in the future.
Investor Verification Checklist
- Regulatory Resolution: Verify the status of the FDA Form 483 observations issued in July 2024 and the company's remediation plan to ensure no further enforcement actions (e.g., consent decrees) are imminent.
- Reimbursement Stability: Monitor CMS reimbursement rate updates for 2025 and the impact of the decrease in CPT code 93229 rates on the Mobile Cardiac Telemetry (MCT) service line.
- Legal Exposure: Track the progress of the securities class action lawsuit and the patent infringement suits filed by Baxter subsidiaries, as adverse outcomes could result in significant financial liability.
- BioIS Integration: Assess the commercial viability and regulatory milestone achievement of the BioIntelliSense technology license, given the $32.4 million immediate expense and $40 million in convertible notes.
- Cash Burn vs. Liquidity: While liquidity is strong ($535.6 million in cash/securities), verify the sustainability of the operating loss trajectory and the timeline to profitability given the high fixed cost structure.